首页 | 本学科首页   官方微博 | 高级检索  
     

子宫内膜癌患者人附睾蛋白4含量变化及其与肿瘤组织中凋亡分子表达的相关性
引用本文:姚玮,卫兵,付娟娟,苏倩. 子宫内膜癌患者人附睾蛋白4含量变化及其与肿瘤组织中凋亡分子表达的相关性[J]. 安徽医药, 2017, 38(7): 844-847
作者姓名:姚玮  卫兵  付娟娟  苏倩
作者单位:230601 合肥 安徽医科大学第二附属医院妇产科,230601 合肥 安徽医科大学第二附属医院妇产科,230601 合肥 安徽医科大学第二附属医院妇产科,230601 合肥 安徽医科大学第二附属医院妇产科
摘    要:
目的 探讨子宫内膜癌患者血清人附睾蛋白4(HE4)含量变化及其与肿瘤组织中凋亡分子表达的相关性。方法 收集2015年9月至2016年9月安徽医科大学第二附属医院收治的子宫内膜癌患者38例,根据病理分期将其分为早期子宫内膜癌组(Ⅰ期)30例、中晚期子宫内膜癌组(Ⅱ~Ⅳ期)8例;另取同期在安徽医科大学第二附属医院门诊接受诊刮治疗的良性疾病患者50例作为对照组。采用电化学发光法测定HE4含量;采用荧光定量PCR法检测肿瘤组织促凋亡基因、抗凋亡基因mRNA表达量。结果 早期子宫内膜癌组和中晚期子宫内膜癌组患者血清HE4含量分别为(125.64±15.82) pmol/L、(243.25±46.83) pmol/L,均高于对照组的(57.38±6.91) pmol/L(P<0.05)。早期子宫内膜癌组、中晚期子宫内膜癌组患者肿瘤组织中促凋亡基因XAF1、ITLN-1 mRNA表达量及Caspase-3蛋白表达量低于对照组,中晚期子宫内膜癌组患者以上分子mRNA表达量低于早期子宫内膜癌组(P<0.05);早期子宫内膜癌组、中晚期子宫内膜癌组患者肿瘤组织抗凋亡基因Survivin、c-myb、Bax、RLIP76、PTP1B mRNA表达量高于对照组患者,中晚期子宫内膜癌组患者以上分子的mRNA表达量高于早期子宫内膜癌组患者(P<0.05)。经Pearson检验,子宫内膜癌患者血清HE4含量与肿瘤组织促凋亡基因及Caspase-3蛋白表达量呈负相关,与肿瘤组织抗凋亡基因表达量呈正相关。结论 子宫内膜癌患者血清中存在异常高表达的HE4,且其表达量与肿瘤恶性程度直接相关。

关 键 词:子宫内膜癌  人附睾分泌蛋白4  凋亡分子
收稿时间:2016-11-20

Changes of serum HE4 in endometrial carcinoma patients and its relationship with apoptosis moleculars expression intumor tissues
YAO Wei,WEI Bing,FU Juanjuan. Changes of serum HE4 in endometrial carcinoma patients and its relationship with apoptosis moleculars expression intumor tissues[J]. Anhui Medical and Pharmaceutical Journal, 2017, 38(7): 844-847
Authors:YAO Wei  WEI Bing  FU Juanjuan
Affiliation:Department of Obstetrics and Gynecology, the Second Hospital of Anhui Medical University, Hefei 232000, China,Department of Obstetrics and Gynecology, the Second Hospital of Anhui Medical University, Hefei 232000, China,Department of Obstetrics and Gynecology, the Second Hospital of Anhui Medical University, Hefei 232000, China and Department of Obstetrics and Gynecology, the Second Hospital of Anhui Medical University, Hefei 232000, China
Abstract:
Objective To study the serum content of HE4 in endometrial carcinoma patients and its relationship with tumor expression of apoptosis factor.Methods Forty cases of endometrial carcinoma patients in our hospital during September 2015 to September 2016 were collected and divided into early-mid-phase endometrial carcinoma group with 30 cases and advanced endometrial carcinoma group(IV) with 10 cases; another 50 cases of patients with uterine benign diseases in our hospital were chosen as control group. All patients'' ser-um content of HE4 was detected by electrochemical luminescence method, and the expression of mRNA in the tumor tissues was detected by Real-time PCR. Results The content ofserum HE4 of in early-mid-phase endometrial carcinoma group and advanced endometrial carcinoma group was(125.64±15.82)pmol/L,(243.25±46.83)pmol/L,respectively, which was higher than (57.38±6.91)pmol/L of control group (P<0.05).mRNA expression of tumor apoptosis promoting genes such as XAF1, ITLN-1 and Caspase-3 proteinwas lower in early-mid-phase endometrial carcinoma group, advanced endometrial carcinoma group than that in control group, and the expression of genes above was lower in advanced endometrial carcinoma group than that in early-mid-phase endometrial carcinoma group(P<0.05).mRNA expression of tumor anti-apoptotic genes such as Survivin, c-Myb, Bax, RLIP76, PTP1Bwas higher in early-mid-phase endometrial carcinoma group, advanced endometrial carcinoma group than that in control group,and the expression of genes above was higher in advanced endometrial carcinoma group than that in early-mid-phase endometrial carcinoma group(P<0.05). The Pearson test showed that the content of serum HE4 in endometrial carcinoma patients was negatively correlated with the expression of Pro apoptotic gene and Caspase-3 protein in tumor tissues, and was positively correlated with the expression of anti apoptotic gene in tumor tissues.Conclusion There is an abnormal high expression of serum HE4 in endometrial carcinoma patients, and its expression is directly related to the malignant degree of the tumor.
Keywords:Endometrial carcinoma  Human epididymis protein 4(HE4)  Apoptosis factor
点击此处可从《安徽医药》浏览原始摘要信息
点击此处可从《安徽医药》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号